证券代码：301122 证券简称：采纳股份 公告编号：2026-011 采纳科技股份有限公司 上述专利的取得和运用，不会对公司短期的经营业绩构成重大影响，但有利 于公司进一步完善知识产权保护体系，形成持续创新机制，保持技术的领先地位， 提升公司的核心竞争力。 特此公告。 采纳科技股份有限公司董事会 2026 年 2 月 26 日 1 / 1 关于控股子公司取得专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）控股子公司江西丰临医疗科技 股份有限公司（以下简称"丰临医疗"）及其全资子公司江西丰临医用器械有限 公司（以下简称"丰临医用"），于近日收到国家知识产权局颁发的专利证书， 具体情况如下： | 序号 | 专利名称 | 专利类型 | 专利号 | 专利权人 | 授权公告日 | | | --- | --- | --- | --- | --- | --- | --- | | 1 | 一种防针刺安全留 | 发明专利 | ZL | 丰临医疗 | 2026 年 月 | 02 | | | 置针组装设备 | | 20231 ...

Group 1 - The company, CaiNa Co., reported that as of February 13, 2026, the number of shareholders is 6,903 [2]

证券代码：301122 证券简称：采纳股份 公告编号：2026-010 采纳科技股份有限公司 关于部分募集资金专户完成销户的公告 1 / 3 | | | | 产业园建设项目 | | | --- | --- | --- | --- | --- | | 3 | 江苏江阴农村商业银行 股份有限公司祝塘支行 | 018801240018202 | 研发中心建设项目 | 已注销 | | 4 | 中国农业银行股份有限 公司江阴华士支行 | 10641401040019320 | 补充流动资金项目 | 已注销 | | 5 | 招商银行股份有限公司 江阴支行 | 511902989110201 | 超额募集资金 | 已注销 | | 6 | 宁波银行股份有限公司 江阴支行 | 78040122000429159 | 超额募集资金 | 已注销 | | 7 | 上海浦东发展银行江阴 | 92060078801400000785 | 年产 9.2 亿支（套） 医用注射穿刺器械 | 已注销 | | | 澄东支行 | | 产业园建设项目 | | | 8 | 江苏江阴农村商业银行 股份有限公司祝塘支行 | 018801240018426 ...

Core Viewpoint - The article discusses the development and regulatory landscape of the pet chip industry in China, highlighting the importance of pet chips for pet management and public safety, as well as the evolving policies at both national and local levels [1][5][7]. Policy Development Timeline - The pet chip industry in China began pilot programs in 2010, focusing on dog management to address issues like urban dog population statistics and rabies prevention. By 2019, many regions implemented dog management regulations that emphasized the use of electronic identification (pet chips) [3]. - In 2024, Shenzhen's regulations mandate that all dogs, except for certain exceptions, must be implanted with electronic tags, reinforcing the importance of pet chips in public safety and management [3][9]. National Policy Summary - Currently, there are no direct national policies specifically targeting the pet chip industry; it falls under the broader pet economy sector. However, relevant regulations include customs announcements that require pets to be microchipped for identification when entering the country [5][6]. - Key national policies include the "Pet Feed Labeling Regulations" and "Pet Feed Hygiene Regulations," which aim to standardize pet food labeling and hygiene standards [6]. Local Policy Summary - Several provinces, including Shandong, Guangdong, Chongqing, Fujian, and Guizhou, have implemented mandatory pet chip implantation policies. For instance, Shandong's regulations require all registered dogs to have electronic chips as identification [7][9]. - Guangdong's regulations specify that all dogs must be microchipped and registered, with detailed management protocols established for pet ownership [9][10]. Development Goals - The regulations aim to standardize dog management, ensure public health and safety, and maintain social order. Local governments are actively promoting the pet chip industry to enhance pet management practices [12][13].

Core Viewpoint - The company, Canar Medical, is experiencing a decline in revenue and profit, with a significant reliance on overseas sales benefiting from the depreciation of the RMB [3][7]. Group 1: Company Overview - Canar Medical specializes in the research, production, and sales of injection and puncture instruments, as well as laboratory consumables, with main products including puncture needles, syringes, laboratory consumables, and masks [2][7]. - The company began supplying IVF culture tubes to Thermo Fisher in 2018 [2]. - As of January 30, the number of shareholders is 6,957, a decrease of 2.08%, while the average circulating shares per person increased by 2.13% [7]. Group 2: Financial Performance - For the period from January to September 2025, Canar Medical reported revenue of 246 million yuan, a year-on-year decrease of 15.86%, and a net profit attributable to shareholders of 8.25 million yuan, down 85.64% year-on-year [7]. - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [8]. Group 3: Market Activity - On February 13, Canar Medical's stock price fell by 0.06%, with a trading volume of 61.59 million yuan and a turnover rate of 2.52%, resulting in a total market capitalization of 3.911 billion yuan [1]. - The stock has seen a net inflow of 2.74 million yuan from major investors today, with a ranking of 19 out of 138 in its industry, although the industry overall has experienced a net outflow of 461 million yuan [4][5]. Group 4: Technical Analysis - The average trading cost of the stock is 28.95 yuan, with the stock price currently near a support level of 31.49 yuan, indicating potential for a rebound if this level holds [6].

证券代码：301122 证券简称：采纳股份 公告编号：2026-009 采纳科技股份有限公司 关于使用部分闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）召开的第三届董事会第十八次 会议、2026 年第一次临时股东会，分别审议通过了《关于使用部分闲置募集资 金和自有资金进行现金管理的议案》，同意公司及全资子公司在确保不影响募集 资金投资项目和公司正常经营，并有效控制风险的前提下，使用额度不超过人民 币 2,000 万元（含本数）的闲置募集资金和额度不超过人民币 80,000 万元（含 本数）的自有资金进行现金管理。使用期限自股东会审议通过之日起 12 个月内 有效。在上述额度和期限内，资金可循环滚动使用。 同时，在额度范围内授权公司管理层行使相关投资决策权并签署相关文件， 具 体 由 公 司 财 务 部 负 责 组 织 实 施 。 具 体 内 容 详 见 公 司 在 巨 潮 资 讯 网 （www.cninfo.com.cn）披露的相关公告。 注：公司与上述受托方无关联关系。 一、本次使用部 ...

Core Viewpoint - The company, Canar Medical, has seen a stock price increase of 3.14% with a trading volume of 140 million yuan and a market capitalization of 3.897 billion yuan, benefiting from the depreciation of the RMB and its focus on the medical device sector, particularly in assisted reproduction [1][2][3]. Company Overview - Canar Medical Co., Ltd. specializes in the research, production, and sales of medical and veterinary injection and puncture devices, as well as laboratory consumables. The main products include puncture needles, syringes, laboratory consumables, and masks [2][7]. - The company began supplying IVF culture tubes to Thermo Fisher in 2018, indicating a strategic partnership in the assisted reproduction market [2]. - As of January 30, the number of shareholders is 6,957, a decrease of 2.08%, with an average of 10,872 circulating shares per person, an increase of 2.13% [7]. Financial Performance - For the period from January to September 2025, Canar Medical reported a revenue of 246 million yuan, a year-on-year decrease of 15.86%, and a net profit attributable to shareholders of 8.25 million yuan, down 85.64% year-on-year [7]. - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [8]. Market Position and Trends - The company has a high overseas revenue ratio of 90.61%, benefiting from the depreciation of the RMB [3]. - The average trading cost of the stock is 28.77 yuan, with recent accumulation activity noted, although the strength of this accumulation is weak. The current stock price is near a support level of 31.49 yuan, which is critical for potential rebound or further decline [6].

Group 1 - The core point of the article is that the company, CaiNa Technology Co., Ltd., has received a patent for a "backflow prevention blood collection needle" from the National Intellectual Property Administration of China [1] - The patent was granted to Jiangsu CaiNa Medical Technology Co., Ltd., a wholly-owned subsidiary of CaiNa Technology [1] Group 2 - The article also highlights the trend of young executives, specifically those born in the 2000s, taking on significant roles in A-share companies, which poses a challenge to meet investor expectations [1] - A specific example mentioned is a 26-year-old who has recently returned from studying at a prestigious American university and has assumed the roles of chairman and general manager [1]

关于全资子公司取得专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）全资子公司江苏采纳医疗科技 有限公司（以下简称"采纳医疗"），于近日收到国家知识产权局颁发的专利证 书，具体情况如下： | 序号 | 专利名称 | 专利类型 | 专利号 | 专利权人 | 授权公告日 | | --- | --- | --- | --- | --- | --- | | 1 | 防回流采血针 | 实用新型 | ZL | 采纳医疗 | 2026 年 02 月 | | | | | 202422639555.2 | | 06 日 | 上述专利为公司自主研发，其所涉及技术均与公司主营业务产品技术相关， 专利权自授权公告之日起生效。 证券代码：301122 证券简称：采纳股份 公告编号：2026-008 采纳科技股份有限公司 上述专利的取得和运用，不会对公司短期的经营业绩构成重大影响，但有利 于公司进一步完善知识产权保护体系，形成持续创新机制，保持技术的领先地位， 提升公司的核心竞争力。 特此公告。 采纳科技股份有限公司董事会 2026 ...

Core Insights - The global pet chip market is experiencing significant growth, driven by increasing demand for pet identification and recovery solutions, with a projected market size of approximately 4.6 billion yuan in 2024 and expected to exceed 10.5 billion yuan by 2030 [7][10]. Group 1: Global Pet Chip Frequency Composition - The frequency composition of global pet chips is highly concentrated, with 134.2 kHz being the dominant frequency, accounting for 81% of the market, followed by 125 kHz at 16%, and 128 kHz at only 3% [1]. Group 2: Global Pet Chip Implantation Rate - North America leads in pet chip implantation rates at 80%, attributed to a mature pet management system and legislative requirements for chip implantation, while China has a low rate of less than 5% due to the absence of national mandates and awareness issues among pet owners [3]. Group 3: Proportion of Implanted Chips in Dogs vs. Cats - Globally, the proportion of implanted chips in dogs is generally higher than in cats, with dogs making up 90% of implanted pets in China, compared to only 10% for cats. This disparity is influenced by pet management regulations and the activity levels of different pet types [6]. Group 4: Global Pet Chip Market Size - The global pet chip market is projected to reach approximately 4.6 billion yuan by 2024, driven by regulatory changes and increased awareness among pet owners regarding the benefits of chip implantation [7]. Group 5: Future Market Size Forecast - The global pet chip market is expected to grow rapidly from 2025 to 2030, with a compound annual growth rate (CAGR) of 15%, leading to a market size exceeding 10.5 billion yuan by 2030 [10].